Ibrutinib inhibits BTK-driven NF-κB p65 activity to overcome bortezomib-resistance in multiple myeloma

Overcoming bortezomib resistance in multiple myeloma

(2014) Megan Y. Murray et al.   BIOCHEMICAL SOCIETY TRANSACTIONS

Osteoblastic niche supports the growth of quiescent multiple myeloma cells

(2014) Z. Chen et al.   BLOOD

Ibrutinib: First Global Approval

(2014) Fiona Cameron et al.   DRUGS

Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes

(2013) J. A. Dubovsky et al.   BLOOD

Identification of Bruton's tyrosine kinase as a therapeutic target in acute myeloid leukemia

(2013) S. A. Rushworth et al.   BLOOD

A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma

(2013) Maria T. Petrucci et al.   BRITISH JOURNAL OF HAEMATOLOGY

The Bruton tyrosine kinase (BTK) inhibitor PCI-32765 synergistically increases proteasome inhibitor activity in diffuse large-B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) cells sensitive or resistant to bortezomib

(2013) Girija Dasmahapatra et al.   BRITISH JOURNAL OF HAEMATOLOGY

Attenuation of dexamethasone-induced cell death in multiple myeloma is mediated by miR-125b expression

(2013) Megan Murray et al.   CELL CYCLE

Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma

(2013) Michael L. Wang et al.   NEW ENGLAND JOURNAL OF MEDICINE

Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia

(2013) John C. Byrd et al.   NEW ENGLAND JOURNAL OF MEDICINE

Bortezomib Resistance Can Be Reversed by Induced Expression of Plasma Cell Maturation Markers in a Mouse In Vitro Model of Multiple Myeloma

(2013) Holly A. F. Stessman et al.   PLoS One

The high Nrf2 expression in human acute myeloid leukemia is driven by NF- B and underlies its chemo-resistance

(2012) S. A. Rushworth et al.   BLOOD

Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma

(2012) Y.-T. Tai et al.   BLOOD

Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides

(2012) J. B. Egan et al.   BLOOD

Clonal competition with alternating dominance in multiple myeloma

(2012) J. J. Keats et al.   BLOOD

Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma

(2012) D. J. Kuhn et al.   BLOOD

BTK inhibitor ibrutinib is cytotoxic to myeloma and potently enhances bortezomib and lenalidomide activities through NF-κB

(2012) Stuart A. Rushworth et al.   CELLULAR SIGNALLING

Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies

(2012) Ranjana H. Advani et al.   JOURNAL OF CLINICAL ONCOLOGY

Minor clone provides a reservoir for relapse in multiple myeloma

(2012) F Magrangeas et al.   LEUKEMIA

Bortezomib Combination Therapy in Multiple Myeloma

(2012) Prashant Kapoor et al.   SEMINARS IN HEMATOLOGY

Treatment Options for Relapsed and Refractory Multiple Myeloma

(2011) Sagar Lonial et al.   CLINICAL CANCER RESEARCH

Shifts in the Therapeutic Paradigm for Patients Newly Diagnosed with Multiple Myeloma: Maintenance Therapy and Overall Survival

(2011) Antonio Palumbo et al.   CLINICAL CANCER RESEARCH

Initial genome sequencing and analysis of multiple myeloma

(2011) Michael A. Chapman et al.   NATURE

NF-κB–Inhibited Acute Myeloid Leukemia Cells Are Rescued from Apoptosis by Heme Oxygenase-1 Induction

(2010) Stuart A. Rushworth et al.   CANCER RESEARCH

Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma

(2010) R. Eric Davis et al.   NATURE

The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy

(2010) L. A. Honigberg et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Multiple myeloma

(2009) Marc S Raab et al.   LANCET

Proteasome-dependent autoregulation of Bruton tyrosine kinase (Btk) promoter via NF- B

(2008) L. Yu et al.   BLOOD

Molecular basis of bortezomib resistance: proteasome subunit  5 (PSMB5) gene mutation and overexpression of PSMB5 protein

(2008) R. Oerlemans et al.   BLOOD

Bortezomib-Resistant Nuclear Factor- B Activity in Multiple Myeloma Cells

(2008) S. Markovina et al.   MOLECULAR CANCER RESEARCH